VanEck Biotech ETF
ETF
BBH
Price as of:
$158.96
+ $0.65
+ 0.41%
Primary Theme
fund company
Name
As of 12/24/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
Vitals
YTD Return
-3.1%
1 yr return
-1.9%
3 Yr Avg Return
-5.3%
5 Yr Avg Return
2.6%
Net Assets
$421 M
Holdings in Top 10
70.3%
52 WEEK LOW AND HIGH
$158.3
$151.99
$182.72
Expenses
OPERATING FEES
Expense Ratio 0.35%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover 41.00%
Redemption Fee N/A
Min Investment
Standard (Taxable)
N/A
IRA
N/A
Fund Classification
Fund Type
Exchange Traded Fund
Name
As of 12/24/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
BBH - Profile
Distributions
- YTD Total Return -3.1%
- 3 Yr Annualized Total Return -5.3%
- 5 Yr Annualized Total Return 2.6%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio 0.23%
- Dividend Yield 0.8%
- Dividend Distribution Frequency Annual
Fund Details
-
Legal NameVanEck Biotech ETF
-
Fund Family NameVANECKFUND
-
Inception DateDec 20, 2011
-
Shares Outstanding2996503
-
Share ClassN/A
-
CurrencyUSD
-
Domiciled CountryUS
-
ManagerPeter Liao
Fund Description
The Fund normally invests at least 80% of its total assets in securities that comprise the Fund’s benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. To be initially eligible for the Biotech Index, companies must generate at least 50% of their revenues from biotechnology. Biotechnology includes companies engaged primarily in research (including research contractors) and development as well as production, marketing and sales of drugs based on genetic analysis and diagnostic equipment (excluding pharmacies). Of the largest 50 stocks in the biotechnology industry by full market capitalization, the top 25 by free-float market capitalization (i.e., includes only shares that are readily available for trading in the market) and three month average daily trading volume are included in the Biotech Index. As of December 31, 2023, the Biotech Index included 23 securities of companies with a market capitalization range of between
approximately $4.9 billion and $154.1 billion and a weighted average market capitalization of $69.1 billion. These amounts are subject to change. The Fund’s 80% investment policy is non-fundamental and may be changed without shareholder approval upon 60 days’ prior written notice to shareholders.
The Fund, using a “passive” or indexing investment approach, attempts to approximate the investment performance of the Biotech Index by investing in a portfolio of securities that generally replicates the Biotech Index. Unlike many investment companies that try to “beat” the performance of a benchmark index, the Fund does not try to “beat” the Biotech Index and does not seek temporary defensive positions that are inconsistent with its investment objective of seeking to replicate the Biotech Index.
The Fund is classified as a non-diversified fund under the Investment Company Act of 1940, as amended (the “Investment Company Act of 1940”) and, therefore, may invest a greater percentage of its assets in a particular issuer. The Fund may concentrate its investments in a particular industry or group of industries to the extent that the Biotech Index concentrates in an industry or group of industries. As of September 30, 2023, each of the biotechnology and life sciences tools & services industries represented a significant portion of the Fund.
BBH - Performance
Return Ranking - Trailing
| Period | BBH Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -3.1% | -26.9% | 19.0% | 86.16% |
| 1 Yr | -1.9% | -26.9% | 19.1% | 87.42% |
| 3 Yr | -5.3%* | -27.9% | 7.4% | 81.58% |
| 5 Yr | 2.6%* | -11.3% | 11.4% | 77.18% |
| 10 Yr | 3.8%* | -0.6% | 12.6% | 84.96% |
* Annualized
Return Ranking - Calendar
| Period | BBH Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | 3.5% | -12.6% | 19.0% | 40.25% |
| 2022 | -15.6% | -53.9% | 3.2% | 75.00% |
| 2021 | 11.6% | -39.6% | 24.2% | 17.76% |
| 2020 | 21.7% | -13.6% | 178.2% | 24.16% |
| 2019 | 25.9% | 3.8% | 63.8% | 21.80% |
Total Return Ranking - Trailing
| Period | BBH Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -3.1% | -26.9% | 19.0% | 86.16% |
| 1 Yr | -1.9% | -26.9% | 19.1% | 87.42% |
| 3 Yr | -5.3%* | -27.9% | 7.4% | 81.58% |
| 5 Yr | 2.6%* | -11.3% | 11.4% | 77.18% |
| 10 Yr | 3.8%* | -0.6% | 12.6% | 84.96% |
* Annualized
Total Return Ranking - Calendar
| Period | BBH Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | 3.9% | -12.6% | 19.0% | 52.83% |
| 2022 | -15.2% | -53.9% | 3.7% | 79.61% |
| 2021 | 11.8% | -33.9% | 26.0% | 34.21% |
| 2020 | 22.1% | -0.7% | 180.6% | 51.68% |
| 2019 | 26.3% | 4.6% | 63.8% | 45.86% |
BBH - Holdings
Concentration Analysis
| BBH | Category Low | Category High | BBH % Rank | |
|---|---|---|---|---|
| Net Assets | 421 M | 6.43 M | 45.7 B | 57.86% |
| Number of Holdings | 25 | 25 | 430 | 100.00% |
| Net Assets in Top 10 | 318 M | 2.55 M | 23.9 B | 55.97% |
| Weighting of Top 10 | 70.28% | 18.9% | 78.1% | 3.14% |
Top 10 Holdings
- Amgen Inc 16.76%
- Vertex Pharmaceuticals Inc 9.94%
- Gilead Sciences Inc 9.17%
- Regeneron Pharmaceuticals Inc 8.57%
- IQVIA Holdings Inc 5.05%
- Argenx SE 4.59%
- ICON PLC 4.47%
- Biogen Inc 4.24%
- Moderna Inc 3.82%
- Illumina Inc 3.67%
Asset Allocation
| Weighting | Return Low | Return High | BBH % Rank | |
|---|---|---|---|---|
| Stocks | 99.93% | 89.92% | 106.13% | 8.18% |
| Cash | 0.07% | 0.00% | 33.01% | 92.45% |
| Preferred Stocks | 0.00% | 0.00% | 7.86% | 61.01% |
| Other | 0.00% | -22.99% | 23.24% | 59.75% |
| Convertible Bonds | 0.00% | 0.00% | 0.37% | 45.45% |
| Bonds | 0.00% | 0.00% | 12.39% | 58.49% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | BBH % Rank | |
|---|---|---|---|---|
| Healthcare | 100.00% | 59.26% | 100.00% | 22.08% |
| Utilities | 0.00% | 0.00% | 0.00% | 39.61% |
| Technology | 0.00% | 0.00% | 22.69% | 44.16% |
| Real Estate | 0.00% | 0.00% | 5.89% | 43.51% |
| Industrials | 0.00% | 0.00% | 7.02% | 43.51% |
| Financial Services | 0.00% | 0.00% | 1.60% | 57.14% |
| Energy | 0.00% | 0.00% | 0.00% | 39.61% |
| Communication Services | 0.00% | 0.00% | 9.11% | 42.86% |
| Consumer Defense | 0.00% | 0.00% | 25.73% | 46.75% |
| Consumer Cyclical | 0.00% | 0.00% | 1.92% | 43.51% |
| Basic Materials | 0.00% | 0.00% | 7.16% | 59.74% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | BBH % Rank | |
|---|---|---|---|---|
| US | 99.93% | 61.27% | 104.41% | 6.29% |
| Non US | 0.00% | 0.00% | 34.10% | 81.76% |
BBH - Expenses
Operational Fees
| BBH Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 0.35% | 0.08% | 4.48% | 93.71% |
| Management Fee | 0.35% | 0.03% | 1.25% | 6.29% |
| 12b-1 Fee | N/A | 0.00% | 1.00% | N/A |
| Administrative Fee | N/A | 0.03% | 0.25% | N/A |
Sales Fees
| BBH Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 3.50% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 1.00% | N/A |
Trading Fees
| BBH Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 1.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| BBH Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 41.00% | 0.00% | 238.00% | 42.96% |
BBH - Distributions
Dividend Yield Analysis
| BBH | Category Low | Category High | BBH % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.79% | 0.00% | 6.24% | 29.56% |
Dividend Distribution Analysis
| BBH | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annual | Annual | Annual | Annual |
Net Income Ratio Analysis
| BBH | Category Low | Category High | BBH % Rank | |
|---|---|---|---|---|
| Net Income Ratio | 0.23% | -2.54% | 1.85% | 24.34% |
Capital Gain Distribution Analysis
| BBH | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Annually | Annually |
Distributions History
| Date | Amount | Type |
|---|---|---|
| Dec 23, 2024 | $1.252 | OrdinaryDividend |
| Dec 18, 2023 | $0.713 | OrdinaryDividend |
| Dec 19, 2022 | $0.749 | OrdinaryDividend |
| Dec 20, 2021 | $0.397 | OrdinaryDividend |
| Dec 21, 2020 | $0.608 | OrdinaryDividend |
| Dec 23, 2019 | $0.472 | OrdinaryDividend |
| Dec 20, 2018 | $0.551 | OrdinaryDividend |
| Dec 18, 2017 | $0.683 | OrdinaryDividend |
| Dec 19, 2016 | $0.327 | OrdinaryDividend |
| Dec 21, 2015 | $0.337 | OrdinaryDividend |
| Dec 23, 2013 | $0.003 | OrdinaryDividend |
| Dec 24, 2012 | $0.166 | CapitalGainShortTerm |
| Dec 24, 2012 | $0.018 | OrdinaryDividend |
| Dec 06, 2012 | $0.060 | ExtraDividend |
| Nov 13, 2012 | $0.212 | OrdinaryDividend |
| Sep 05, 2012 | $0.006 | OrdinaryDividend |
| Aug 29, 2012 | $1.140 | OrdinaryDividend |
| Aug 14, 2012 | $0.212 | OrdinaryDividend |
| May 14, 2012 | $0.232 | OrdinaryDividend |
| Mar 07, 2012 | $0.026 | OrdinaryDividend |
| Nov 15, 2011 | $0.060 | OrdinaryDividend |
| Sep 07, 2011 | $0.002 | OrdinaryDividend |
| Aug 16, 2011 | $0.060 | OrdinaryDividend |
| May 26, 2011 | $0.107 | ExtraDividend |
| Apr 26, 2011 | $3.453 | ExtraDividend |
| Mar 09, 2011 | $0.001 | OrdinaryDividend |
| Oct 29, 2009 | $0.460 | ExtraDividend |
| Sep 09, 2009 | $0.001 | OrdinaryDividend |
| Apr 01, 2009 | $27.867 | ExtraDividend |
| Mar 11, 2009 | $0.005 | OrdinaryDividend |
| Dec 03, 2008 | $1.089 | ExtraDividend |
| May 21, 2008 | $1.000 | ExtraDividend |
| Mar 12, 2008 | $0.004 | OrdinaryDividend |
| Jun 27, 2007 | $2.900 | ExtraDividend |
| Mar 14, 2007 | $0.004 | OrdinaryDividend |
| Feb 05, 2007 | $0.453 | ExtraDividend |
| Apr 26, 2006 | $2.560 | ExtraDividend |
| Jul 17, 2002 | $0.630 | ExtraDividend |
| Feb 27, 2002 | $0.003 | OrdinaryDividend |
| Aug 30, 2000 | $0.003 | OrdinaryDividend |
BBH - Fund Manager Analysis
Managers
Peter Liao
Start Date
Tenure
Tenure Rank
Dec 20, 2011
10.45
10.5%
Mr. Liao has been employed by Van Eck Associates Corporation as an analyst since the summer of 2004 and has been a portfolio manager since 2006. Mr. Liao graduated from New York University in 2004 with a Bachelor of Arts in Economics and Mathematics. He is a CFA charterholder.
Guo Hua (Jason) Jin
Start Date
Tenure
Tenure Rank
Feb 01, 2018
4.33
4.3%
Guo Hua (Jason) Jin has been employed by Van Eck Associates Corporation as an analyst since January 2007 and has been a portfolio manager since 2018. Mr. Jin graduated from the State University of New York at Buffalo in 2004 with a Bachelor of Science degree in Business Administration with a concentration in Financial Analysis.
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.02 | 24.72 | 7.88 | 0.25 |